NTRA reports today against a backdrop where its own chief executive has been a notable seller — and that insider activity is the most striking signal heading into the release.
CEO Steven Chapman sold roughly $4.8 million worth of shares on June 4 across multiple tranches, at prices ranging from $217 to $226. That came just days before the print, and just days after an independent director, Gail Boxer Marcus, sold a further $2.4 million. Combined, the insider ledger shows net selling in the 90-day window totalling around $30 million in value. The stock has since slipped off those levels, closing at $216.50 on Wednesday — down nearly 3% on the day though still up 11% over the past month.
The analyst picture is more constructive than the insider activity suggests. Goldman Sachs kicked off coverage on June 5 with a Neutral rating and a $245 target, while Wolfe Research assumed coverage just days earlier at Outperform with a $260 target. After the last earnings print on May 7, JPMorgan and Evercore both lifted their targets to $265 and $270 respectively. The Street consensus sits at $259 on average — roughly 20% above the current price — pointing to broad acknowledgement that Natera's growth story in prenatal and minimal residual disease testing has further to run. The debate is less about direction and more about pace: bulls see accelerating MRD adoption and pharmaceutical partnerships as compounding drivers, while bears flag rising competition from BillionToOne and GeneDx in women's health testing, execution risk on spending, and reimbursement uncertainty as meaningful offsets.
The last print does offer a relevant data point. When Natera reported in May, the stock fell nearly 10% on the day and extended those losses to roughly 8.5% over the following five sessions — even though subsequent analyst target raises suggest the market overreacted to something in the numbers rather than the underlying thesis. Options positioning today is modestly more defensive than usual: the put/call ratio has climbed to 0.67, running above its 20-day average of 0.59, around one standard deviation elevated. That is a mild signal, not an extreme one. Short interest, at just 2.7% of the free float and continuing to drift lower, adds little pressure from that side. Borrow availability remains extraordinarily loose, so there is no lending-market tension to speak of.
Today's print tests whether Natera can sustain the revenue and MRD volume trajectory that justified the stock's 11% monthly climb — and whether the margin profile has improved enough to quiet concerns about the pace of spending that have trailed the name all year.
See the live data behind this article on ORTEX.
Open NTRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
